ArticleClinical and translational radiation oncology2020

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers.

David S Lakomy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.